Skip to content

Released May 7, 2015, after the close

10-Q filed May 7, 2015, 37 days after period end · 0001104659-15-035555

Q1 2015 · 10-Q
Revenue—
Net Income-$7.88MN/M vs Q1 2014N/M vs Q4 2014
EPS Diluted-$0.38N/M vs Q1 2014N/M vs Q4 2014
Operating Income-$7,324,000N/M
Operating Cash Flow-$6,375,000N/M
Free Cash Flowderived-$6,827,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2015Q1 2014Q1 2013Q1 2012
Revenue——$472.00K$418.00K
Net Income-$7.88M-$6.98M-$3.55M-$3.23M
EPS Diluted-$0.38-$0.34-$2.92-$3.43

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR